Efficacy of semaglutide combined with metformin on BMI reduction Six studies [17,18,21,22,24,25] reported the effect of semaglutide combined with metformin on BMI, and the results showed that the combined treatment resulted in a lower BMI compared to metformin alone (SMD: -1.08
Zhang L, Li Y, Lu W, Meng F, Wu CA, Guo X
This risk was higher in those with prolonged exposure, as well as in males
Parenteral administration is expected to dominate the market, accounting for 80% of the market share in 2026, as GLP-1 Receptor Agonists are commonly administered via injections for better absorption and efficacy
Risk Stratification & Contraindications Patient safety must guide the initiation of GLP-1 therapy, and therapy should be withheld if contraindications are present: Absolute Contraindications: Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Cautionary History: Previous pancreatitis or gastroparesis 5